Everything Blockchain (OTC: EBZT), a technology company that is blending blockchain, DBMS and Zero Trust to deliver disruptive new ways to store, manage and protect data, today announced that Epic Industry Corp, a company owned solely by Michael Hawkins, the Company’s Chairman of the Board, acquired an additional 500,000 shares of the Company’s common stock in a private transaction from a private investor. The shares were acquired at an average price of $4.72 per share, an aggregate purchase price of approximately $2.4 million. Following the transaction, Mr. Hawkins owns 982,500 shares of common stock.

Sidus Space (Nasdaq: SIDU), a Space and Defense-as-a-Service satellite company focused on mission-critical hardware manufacturing; multi-disciplinary engineering services; satellite design, production, launch planning, mission operations; and in-orbit support, announced the appointment of Leonardo Riera to its Board of Directors. Riera, who has served on the boards of many private and public companies, currently serves on the Boards of Directors of Vaya Space, Inc. and of FenixOro Gold. "We are thrilled to welcome Leo to our Board of Directors," said Carol Craig, Sidus Space Founder and CEO. "He brings a wealth of experience in financial services, mergers & acquisitions, and corporate governance that will be invaluable as we continue to grow and expand our business.”

BullFrog AI Holdings (Nasdaq: BFRG; BFRGW), a digital technology company using machine learning to usher in a new era of precision medicine, is pleased to announce its worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for use of patented technology powering the Company’s bfLEAP™ platform.

Inspira Technologies (Nasdaq: IINN), a company aiming to revolutionize acute respiratory care, announced its financial results for the fourth quarter and year ended December 31, 2022. "We believe that the Company is well funded to achieve its immediate goals, advancing the building blocks of the INSPIRATM ART system. This includes the HYLA blood sensor clinical studies currently underway and our ALICE device, with the U.S. Food and Drug Administration (FDA) submission planned to occur in the second half of this year."